Literature DB >> 16166848

Intense esophageal FDG activity caused by Candida infection obscured the concurrent primary esophageal cancer on PET imaging.

Sankaran Shrikanthan1, Aysel Aydin, Thiruvenkatasamy Dhurairaj, Abass Alavi, Hongming Zhuang.   

Abstract

Esophageal cancer frequently causes a focal intense FDG uptake on positron emission tomography (PET) imaging while esophagitis often results in a mild to moderate degree of FDG activity in a diffuse pattern. However, detection of an esophageal cancer can become difficult in the presence of a diffuse esophageal activity because of esophagitis. We present such case in which esophageal cancer superimposed by Candidal esophagitis is difficult to recognize on FDG PET images.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16166848     DOI: 10.1097/01.rlu.0000178244.55482.2a

Source DB:  PubMed          Journal:  Clin Nucl Med        ISSN: 0363-9762            Impact factor:   7.794


  5 in total

Review 1.  Role of ¹⁸F 2-fluoro-2-deoxyglucose positron emission tomography in upper gastrointestinal malignancies.

Authors:  Elizabeth C Smyth; Manish A Shah
Journal:  World J Gastroenterol       Date:  2011-12-14       Impact factor: 5.742

Review 2.  Imaging fungal infections in children.

Authors:  Alfred O Ankrah; Mike M Sathekge; Rudi A J O Dierckx; Andor W J M Glaudemans
Journal:  Clin Transl Imaging       Date:  2016-01-25

3.  Candida Esophagitis Incidentally Detected by 18F-FDG PET/CT in Metastatic Lung Adenocarcinoma.

Authors:  N Martínez-Amador; I Martínez-Rodríguez; R Quirce; J Jiménez-Bonilla; I Banzo
Journal:  Indian J Nucl Med       Date:  2017 Jan-Mar

4.  Importance of diffuse versus focal F-18 fluoro-deoxy-glucose uptake in oesophagus.

Authors:  Sampath Santhosh; Bhagwant Rai Mittal; Anish Bhattacharya; Ashim Das; Rakesh Kochhar
Journal:  Indian J Nucl Med       Date:  2011-10

Review 5.  PET in the diagnostic management of infectious/inflammatory pulmonary pathologies: a revisit in the era of COVID-19.

Authors:  Sanaz Katal; Hamidreza Amini; Ali Gholamrezanezhad
Journal:  Nucl Med Commun       Date:  2021-01       Impact factor: 1.698

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.